The United States market has shown robust growth, climbing 3.2% in the last week and up 31% over the past year, with earnings expected to grow annually by 16%. In this context of strong market performance, identifying stocks with solid financial foundations is crucial for investors looking to capitalize on potential gains. While the term "penny stocks" might seem outdated, these often-overlooked smaller or newer companies can offer unique opportunities for growth when supported by strong balance sheets and fundamentals.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ZJK Industrial (ZJK)	$3.04	$198.76M	✅ 3 ⚠️ 2 View Analysis >
WM Technology (MAPS)	$0.40	$60.49M	✅ 3 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.06	$363.45M	✅ 3 ⚠️ 2 View Analysis >
Information Services Group (III)	$3.11	$197.37M	✅ 3 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.19	$398.83M	✅ 3 ⚠️ 1 View Analysis >
Village Farms International (VFF)	$2.76	$309.63M	✅ 5 ⚠️ 1 View Analysis >
SIGA Technologies (SIGA)	$7.80	$337.1M	✅ 2 ⚠️ 1 View Analysis >
BAB (BABB)	$0.93643	$6.66M	✅ 2 ⚠️ 3 View Analysis >
Marine Petroleum Trust (MARP.S)	$4.85	$9.86M	✅ 2 ⚠️ 4 View Analysis >

Below we spotlight a couple of our favorites from our exclusive screener.

KORU Medical Systems (KRMD)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions for the subcutaneous drug delivery market both in the United States and internationally, with a market cap of $186.52 million.

Operations: KORU Medical Systems does not report distinct revenue segments.

Market Cap: $186.52M

KORU Medical Systems has demonstrated consistent revenue growth, with first-quarter sales reaching US$11.76 million, up from US$9.64 million the previous year. Despite being unprofitable with a net loss of US$0.81 million for the quarter, it maintains a strong cash position and positive cash flow runway exceeding three years. The company recently achieved EU MDR certification for its Freedom60 Infusion Pump, expanding its market reach in Europe and enhancing its product portfolio in subcutaneous immunoglobulin therapy. Leadership transitions are underway as Adam Kalbermatten prepares to assume the CEO role from Linda Tharby by mid-2026.

Braemar Hotels & Resorts (BHR)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Braemar Hotels & Resorts Inc. is a real estate investment trust (REIT) specializing in the luxury hotel and resort sector, with a market cap of approximately $188.75 million.

Operations: Braemar Hotels & Resorts Inc. has not reported any specific revenue segments.

Market Cap: $188.75M

Braemar Hotels & Resorts Inc., a luxury hotel and resort REIT, is trading at a good value compared to peers, despite being unprofitable. It maintains a positive cash flow with a runway exceeding three years and has reduced its debt to equity ratio over five years. However, high net debt remains concerning. Recent earnings showed improved net income of US$17.7 million for Q1 2026 but highlighted ongoing revenue challenges. Investor activism by Al Shams Investments raises governance concerns, urging the board against asset sales that could trigger costly advisory payments and potential conflicts of interest involving Chairman Monty Bennett.

Valens Semiconductor (VLN)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Valens Semiconductor Ltd., along with its subsidiaries, develops semiconductor products for the audio-video and automotive sectors, with a market cap of $263.23 million.

Operations: The company's revenue is derived from two primary segments: Automotive, contributing $18.97 million, and Cross Industry Business (CIB), which accounts for $51.66 million.

Market Cap: $263.23M

Valens Semiconductor, a company focused on semiconductor products for audio-video and automotive sectors, maintains a solid financial position with short-term assets of US$118.7 million exceeding its liabilities. Despite being unprofitable and not expected to achieve profitability in the next three years, it has effectively reduced losses at 4.4% annually over five years and forecasts revenue growth of 17.2% per year. Recent executive changes include the upcoming resignation of CFO Guy Nathanzon by July 2026, while strategic partnerships like that with MCNEX aim to enhance product offerings in cost-sensitive automotive markets using Valens' VA7000 chipsets.

Key Takeaways

• Click here to access our complete index of 342 US Penny Stocks.
• Searching for a Fresh Perspective? We've found 14 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.